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Macrophages display different phenotypes with distinct functions and can rapidly respond
to environmental changes. Previous studies on TRAMP-C1 tumor model have shown that
irradiation has a strong impact on tumor microenvironments. The major changes include
the decrease of microvascular density, the increase of avascular hypoxia, and the aggrega-
tion of tumor-associated macrophages in avascular hypoxic regions. Similar changes were
observed no matter the irradiation was given to tissue bed before tumor implantation (pre-
IR tumors), or to established tumors (IR tumors). Recent results on three murine tumors,
TRAMP-C1 prostate adenocarcinoma, ALTS1C1 astrocytoma, and GL261 glioma, further
demonstrate that different phenotypes of inflammatory cells are spatially distributed into
different microenvironments in both IR and pre-IR tumors. Regions with avascular hypoxia
and central necrosis have CD11bhigh/Gr-1+ neutrophils in the center of the necrotic area.
Next to them are CD11blow/F4/80+ macrophages that sit at the junctions between cen-
tral necrotic and surrounding hypoxic regions. The majority of cells in the hypoxic regions
are CD11blow/CD68+ macrophages. These inflammatory cell populations express differ-
ent levels of Arg I. This distribution pattern, except for neutrophils, is not observed in
tumors receiving chemotherapy or an anti-angiogenesis agent which also lead to avascular
hypoxia. This unique distribution pattern of inflammatory cells in IR tumor sites is inter-
fered with by targeting the expression of a chemokine protein, SDF-1α, by tumor cells,
and this also increases radiation-induced tumor growth delay.This indicates that irradiated-
hypoxia tissues have distinct tumor microenvironments that favor the development of M2
macrophages and that is affected by the levels of tumor-secreted SDF-1α.
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INTRODUCTION
A major obstacle in cancer radiation therapy (RT) or chemother-
apy is the presence of hypoxic tumors, and this could be an even
more serious issue in recurrent tumors in which the hypoxia can
shift from transient to chronic hypoxia (Chen et al., 2011). The
recurrent tumors are not only less responsive to salvage RT or
chemotherapy, but also have a higher risk of metastasis (Vicini
et al., 2003). Although the effects of hypo-perfusion and low
oxygen contents on tumor cells are often blamed for poor treat-
ment response, distinct tumor microenvironments within hypoxic
regions such as where there are more acidic or contain high num-
bers or distinct populations of macrophages, also play significant
roles in tumor resistance to therapy (Jiang et al., 2010; Zhang et al.,
2010; Denardo et al., 2011). Several new treatment protocols to
target the tumor microenvironments have been suggested, such as
pH responsive drug delivery (Chiu et al., 1999; Benoit et al., 2010)
and macrophage-targeted (Ahn et al., 2010; Jiang et al., 2010) or -
assisted (Alizadeh et al., 2010; Muthana et al., 2011) cancer therapy.
However, the improvement of cancer therapy by these approaches
has still to be realized. One critical issue in targeting the tumor
microenvironment is that its changes during or after the therapy.
This continuous and dynamic process is crucial for the right timing
of intervention. We have previously shown that there are temporal
and spatial changes in the subcomponents within tumor microen-
vironments following single or fractionated radiation (Chen et al.,
2009). Better understanding of the dynamic features of hypoxic
microenvironments following RT may provide new strategies to
improve the efficacy of cancer treatment.
One remarkable feature in hypoxic tumor microenvironments
is the large amount of infiltrated macrophages, so-called tumor-
associated macrophages (TAMs). TAMs represent the largest pop-
ulation of infiltrating inflammatory cells in malignant tumors.
They were originally thought of as one host defense mechanism
against the developing cancer. However, evidence has accumu-
lated indicating that TAMs may assist tumors to survive hazardous
environments in various ways (Nishie et al., 1999; Bingle et al.,
2002; Murdoch and Lewis, 2005; Lewis and Pollard, 2006; Li
et al., 2007; Ahn and Brown, 2008; Qian and Pollard, 2010; Chen
et al., 2011) and even promote tumor resistance to chemother-
apy (Zhang et al., 2010; Denardo et al., 2011). Two distinct TAM
phenotypes, M1 or M2, have been described with the abilities to
inhibit or promote tumor growth, respectively. The M1 phenotype
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is proinflammatory and has high levels of iNOS production; the
M2 phenotype (Mantovani et al., 2002) is anti-inflammatory,
pro-angiogenic (Dirkx et al., 2006; Lin et al., 2006), metastasis-
promoting (Leek et al., 1996; Hanada et al., 2000), and has high
levels of Arg I production. However, TAMs may change their
functions under different microenvironments (Stout et al., 2005;
Chiang et al., 2008; Redente et al., 2010). It has been hypothesized
that initial TAMs are predisposed to have M1 function, but are
gradually changed to M2 function as tumor grow (Weigert and
Brune, 2008). This is associated with factors, such as IL-4, IL-10,
TGF-β, PGE2, and chemokines, released by tumor cells in response
to the changes in the microenvironments, in particular the devel-
opment of hypoxia (Mantovani et al., 1986; Lewis et al., 1999).
Furthermore, TAMs within different subcomponents of the same
tumor may also have different functions. Ohno et al. (2003) had
shown that TAMs in different niches of gastric carcinoma have
different influences on patients’ survival, stressing the heterogene-
ity of TAMs and the effects of tumor microenvironment on TAM
function. It has been proposed that M1 and M2 TAMs will seg-
regate to different areas of the tumor, with M2 TAMs migrating
to and aggregating in avascular or hypoxia regions (Lewis and
Murdoch, 2005; Murdoch and Lewis, 2005). This may explain the
variation of M1/M2 ratio and inconsistency in the correlation
of the number of TAMs with the prognosis in different types of
tumor (Bingle et al., 2002). For example, a positive correlation has
been reported in breast and prostate cancer, but a negative corre-
lation in colon caner. Contrary conclusions from the same type
of tumor had also been reported in brain tumors when different
types of surface markers were used (Bingle et al., 2002). These
findings indicate that host or tumor factors may be critical for
assessment of the effects of tumor microenvironments on TAM
function, in particular for tumor re-growth after RT because our
previous studies showed TAMs are actively involved in the remod-
eling of post-radiation microenvironments (Chen et al., 2011).
However, systematic studies on this area are lacking.
The potential of RT to alter TAM phenotype and function has
rarely been studied. In our previous study, TAMs isolated from
irradiated tumors expressed higher Arg I, COX-2, and iNOS levels
than those from un-irradiated tumors and were more effective at
promoting tumor growth (Tsai et al., 2007), indicating more M2
TAMs in irradiated-TRAMP-C1 tumors. In this study, we used
three different murine tumors, TRAMP-C1 prostate adenocarci-
noma, ALTS1C1 astrocytoma, and GL261 glioma, to explore how
irradiation affects the relationship between hypoxia and TAMs and
whether those changes in irradiated tumor microenvironments are
affected by tumor or host factors.
MATERIALS AND METHODS
TUMOR MODEL AND TUMOR IRRADIATION
All experiments were performed using 7- to 8-week-old male
C57BL/6J mice obtained from National Laboratory Animal Center,
Taiwan. The TRAMP-C1 prostate cancer cell line was derived from
transgenic mice with adenocarcinoma of the mouse prostate (Fos-
ter et al., 1997) and was purchased from the ATCC (CRL-2730).
ALTS1C1 was derived from primary astrocytes transformed by
SV40 large T antigen and serial in vivo passage (Wang et al., 2012)
and is deposited in Bioresource Collection and Research Center
(BCRC-60582), Taiwan. GL261 was a generous gift from Prof.
Newcomb, E. W., Departments of Pathology, New York University
School of Medicine (Newcomb et al., 2010). For intramuscular
model, tumors were generated by intramuscular inoculation of
3× 106 viable cells into the thigh. Mice with tumors of 4 mm
in diameter were selected and randomly allocated to groups for
experimentation (tumor diameter was defined by (a+ b)/2, where
a and b are the width of two dimensions of mouse thigh) that con-
tained at least five mice per time point. To implant ALTS1C1 or
GL261 cells into the brain, 2µl containing 1× 105 cells were inoc-
ulated intracranially (i.c.) into 6- to 8-week-old C57BL/6 mice as
described (Wang et al., 2012). Prior to sacrifice, the animals were
anesthetized and then perfused transcardially with PBS followed
by 4% paraformaldehyde. The maximum tumor cross sectional
area was used to compare the tumor growth for i.c. tumor model
and defined by [(a+ b)/2]2×pi, where a and b are the width of
two dimensions of maximum cross section.
The irradiation protocol was as previously described (Tsai et al.,
2007). Tumors were irradiated with either a single dose of 25 Gy
to the intramuscular tumor or 8 Gy to intracranial tumors. The
tumors were removed at indicated times following irradiation.
During the experiments, all mice were cared for in accordance
with the approved guide by the Institutional Animal Care and
Use Committee (IACUC), National Tsing Hua University, Taiwan
(approved number: IACUC:09705).
cDNA MICROARRAY
Total RNA was isolated by PureLink RNA purification system
(Invitrogen) according to the manufacturer’s instructions to gen-
erate cRNA targets. The samples of primary astrocytes and two
cell lines, ALTS1C1, and GL261, were hybridized using Affymetrix
Mouse Genome 430A 2.0 Oligonucleotide Microarrays in the
Genomic Medicine Research Core Laboratory (GMRCL) of Chang
Gung Memorial Hospital (Wang et al., 2004). After scanning,
hybridization signals were collected and the signals that were dif-
ferentially expressed twice as compared with the normal astrocyte
were selected for further analysis.
RT-PCR
Total RNA was extracted with TRIzol (Invitrogen). Two micro-
grams of total RNA was reverse-transcribed using Super Script III
RNase H reverse transcriptase (Invitrogen, CA, USA) and random
hexamer primers (Invitrogen) at 25˚C for 10 min and 42˚C for 1 h.
Two microliters of the reverse transcription product was used as
a template for PCR amplification. PCR was performed using Taq
polymerase (Invitrogen) and 150 nmol/L of primers. The PCR
conditions consisted of 3 min of an initial denaturation step (95˚C
followed by 30 cycles of denaturation (95˚C, 30 s), annealing (57˚C,
30 s), and extension (72˚C, 30 s) followed by a final elongation step
of 10 min at 72˚C. Ten microliters of PCR product was analyzed
on 2% agarose gels stained with ethidium bromide. Quantitation
of bands was done with the Bio-Rad Fluor-S apparatus (Bio-Rad,
Hercules, CA, USA) with Quantity One (version 4.2.1) software.
IMMUNOHISTOCHEMISTRY
Tumor hypoxia was studied by i.v. injection of 4 mg pimonidazole
hydrochloride (Hypoxyprobe™-1 Kit, Hypoxyprobe, Burlington,
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MA, USA) in 0.1 ml solution 1 h before tumor harvest. Tissues
were removed and placed in cold 4% paraformaldehyde overnight
then processing and embedding in paraffin or OCT. Ten microm-
eters cryostat sections were fixed in methanol at−20˚C for 10 min,
and then rehydrated in PBS. Non-specific binding was blocked by
incubating sections in 1% of bovine serum albumin (BSA) in PBS
for 30 min. Tumors sections were double-stained for pimonida-
zole in combination with CD31 or CD68. Pimonidazole (POMO)
was detected with mouse antibody (Hypoxyprobe) and goat anti-
mouse IgGγ1 Alexa 488 (Invitrogen). For endothelial cells, rat
anti-CD31 antibody (BD biosciences,San Jose,CA,USA) was used,
followed by goat anti-rat Alexa 594 (Invitrogen). For macrophages,
rat anti-CD68 (Serotec, Raleigh, NC, USA), anti-F4/80 (Serotec),
or anti-CD206 (Biolegend) was used, followed by goat anti-rat
Alexa 594 (Invitrogen). Slides were rinsed in PBS and mounted
with ProLong® Gold anti-fade reagent (P-36931, Invitrogen).
IMAGE ACQUISITION, PROCESSING, AND ANALYSIS
Immunofluorescent images from each tumor section were cap-
tured using an external digital camera (Dxm 1200C, Nikon, Tokyo,
Japan) on a Nikon fluorescence microscope (Nikon Eclipse TE
2000-S) or an AxioCam MRC-5 camera on an Axiovert40 fluores-
cence microscope (Carl Zeiss, Göttingen, Germany) and processed
using Image-pro plus 6.0 software (MediaCybernetics, Bethesda,
MD, USA). Microvascular density (MVD) was determined as the
number of pixels positive for CD31 divided by the total tumor
area. The hypoxia fraction was defined as the area positive for
pimonidazole divided by the total tumor area (necrosis excluded).
The density of macrophages in the hypoxic region was defined
as the fraction of pixels positive for CD68 in the pimonidazole
positive tumor area divided by the fraction of total CD68 posi-
tive pixels within the selected field. The mean intensity of Arg-1
of CD68 positive TAMs was calculated as the sum of intensity of
Arg-1 that are double positive for Arg-1 and CD68 divided by the
Arg-1 staining color pixels in selected area. The mean intensity of
CD11b positive cells in control tumor was calculated as a reference.
Regions with relative CD11b intensity>125 or<75% of reference
CD11b mean intensity were arbitrarily defined as CD11bhigh or
CD11blow regions, respectively.
STATISTICS
Statistical analyses used GraphPad Prism version 3 (GraphPad
Software, San Diego, CA, USA). For all comparisons, assessment
of statistical significance was by unpaired t -tests with significance
set at P = 0.05.
RESULTS
THE ASSOCIATION OF CD68+ TAMs WITH HYPOXIA IS TUMOR AND
TISSUE DEPENDENT
Murdoch et al. (2004) have shown that CD68+ TAMs were prefer-
ably situated at hypoxic regions in a xenograft model of human
cervix cancer. However, our previous study in TRAMP-C1 model
has shown that CD68+ TAMs do not have any specific pref-
erence for hypoxic or non-hypoxic regions (Chen et al., 2009).
To further clarify this issue, we injected murine astrocytoma,
ALTS1C1, or murine glioma, GL261, murine astrocytoma and
glioma, into the muscle to mimic TRAMP-C1 tumor model. The
result (Figures 1A,B) clearly shows that CD68+ TAMs are ran-
domly distributed within the tumor without any preference for
the hypoxia. However, when ALTS1C1 was implanted into the
brain, a degree of preference for CD68+ TAM to accumulate in
hypoxic regions was found (Figure 1C), but this preference is
not seen for GL261 tumors grown in the brain (Figure 1D). This
result indicates that the association of CD68+ TAMs with hypoxia
is tumor dependent. The differences in distribution pattern for
ALTS1C1 growing in intramuscular versus intracranial sites indi-
cates that the association of TAMs with hypoxia also depends on
local environmental cues.
To further explore whether the association of TAMs with
hypoxia is associated with factors released by tumors, a gene
microarray approach was used to compare the expression pro-
files between ALTS1C1 and GL261 because both display different
TAMs-hypoxia association pattern in the brain (Figure 2A). Fol-
lowing RT-PCR confirmation, the expression levels of, at least
three monocyte-associated factors, SDF-1α, VEGF, and MMP-2,
were identified as different between ALTS1C1 and GL261 tumor
cells (Figure 2B). When the expression of SDF-1α by ALTS1C1
cells was suppressed by the transfection of lentiviral siRNA par-
ticles, the association of CD68+ TAMs with hypoxia disappeared
(Wang et al., 2012). This supports the notion that factors released
by tumor cells can affect the function of TAMs.
SPATIAL DISTRIBUTION OF DIFFERENT SUBSETS OF INFLAMMATORY
CELLS IN IR OR PRE-IR TUMORS
An important finding from our previous study in the TRAMP-
C1 tumor model was aggregation of CD68+ TAMs into chronic
hypoxic regions after RT (Chen et al., 2009). These CD68+
TAMs expressed weaker CD11 staining by IHC but another sub-
type cells with stronger CD11 expression was found within the
necrotic region (Figure 3A). These cells were further demon-
strated to be Gr-1+. Based on the Gr-1 staining and intensity
of CD11b expression by IHC, the CD11b+ cells can be fur-
ther divided into two sub-populations, CD11bhigh/Gr-1+ neu-
trophils and CD11blow/Gr-1− TAMs. The CD11blow TAMs could
be further divided into CD11blow/CD68+ and CD11blow/F4/80+
TAMs. The CD11blow/CD68+ TAMs were highly centered in
PIMO+ regions, and CD11blow/F4/80+TAMs were on the edge of
PIMO+ regions next to necrotic regions. In other words, this study
shows that randomly distributed CD11b cells in un-irradiated con-
trol tumors re-distributed into distinct spatial location after RT.
The flow cytometry assay (Figure 3B) found that the total number
of CD11b cells increased after RT, but this increase was mainly the
result of infiltration of Gr-1+ cells. The number of CD68+ TAMs
during this period showed no significant change over a 3-week
period.
The association of TAMs with hypoxic tumor before and after
RT was further examined using the ALTS1C1 and GL261 brain
tumor models. Figure 4 shows that RT induced the aggregation
of CD68+ TAMs into PIMO+ regions in both ALTS1C1 and
GL261 tumors, which was not seen in control tumors as shown
in Figure 1C versus Figure 1D. This indicates that radiation-
induced hypoxic regions have factors to attract or trap CD68+
TAMs. Actually, the association of CD68+ TAMs with hypoxia is
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FIGURE 1 |The association of CD68+TAMs with hypoxia is tumor and
tissue dependent. The distribution of CD68+TAMs and PIMO+ hypoxia in
ALTS1C1 astrocytoma (A,C) and GL261 glioma (B,D) grown in the thigh (i.m.)
(A,B) or in the brain (i.c.) (C,D). Green: anti-PIMO stain for hypoxic region; red:
anti-CD68 antibody for TAMs. Merged images: the colocalization of hypoxia
and TAMs. Scale bar=100µm.
FIGURE 2 |The gene expression profiles between ALTS1C1 and GL261 cells by (A) cDNA microarray and (B) RT-PCR analysis. The mRNA level of primary
astrocyte was used as reference.
Frontiers in Oncology | Radiation Oncology August 2012 | Volume 2 | Article 89 | 4
Chiang et al. Radiation-induced M2 macrophages
FIGURE 3 | Irradiation redistributes the localization of subtypes
of inflammatory cells. (A) The distribution of CD31, CD11b, Gr-1,
CD68, and F4/80 staining with PIMO+ hypoxia in series
25 Gy-irradiated-TRAMP-C1 tumor sections. Green: anti-PIMO stain
for hypoxic region; red: anti-CD31, anti-CD11b, anti-Gr-1, anti-CD68,
or anti-F4/80 antibody. Merged images: the colocalization of hypoxia
and inflammatory cells or vessels. Scale bar=100µm. (B)
Percentage of CD11b, CD68, F4/80, or Gr-1 positive cells within
control or 25 Gy-irradiated TRAMP-C1 tumors as assayed by flow
cytometry.
not only in irradiated tumors, but also occurs in tumors grow-
ing from pre-irradiated tumor bed, so-called pre-IR tumor. This
is not only seen in TRAMP-C1 tumor model (Chen et al., 2011),
but also occurs in ALTS1C1 astrocytoma tumor growing in either
pre-irradiated brain or muscle tissues (Figure 5).
TAM AGGREGATION INTO AVASCULAR HYPOXIC REGIONS IS A
SPECIFIC EFFECT OF IRRADIATION
Using the pre-IR TRAMP-C1 tumor bed model, we have reported
that the accumulation of TAMs is only seen in PIMO+ hypoxic
areas with low MVD, but not in areas with high MVD regions
(Chen et al., 2011). This challenges us to wonder whether the
decrease of MVD is the prime factor for TAM aggregation. In
fact, the nature of PIMO+ region in control and irradiated tis-
sues is different (Figure 6). In control ALTS1C1 tumor, there are
vessels intervening within the PIMO+ areas (Figures 6A,C) and
the hypoxia is likely to be the result of vessel malfunction. On the
other hand, RT destroys most vessels or alters the way they are
formed within tumors (Chen et al., 2011) and the PIMO+ regions
(Figures 6B,D). ALTS1C1 tumors do not contain vessels whether
the tumor or the tumor bed had been irradiated. In other words,
the hypoxia in irradiated tissues is likely the result of vascular
insufficiency, so-called avascular chronic hypoxia. The avascular
chronic hypoxia could be found in tumors receiving 25 Gy of irra-
diation before or after tumor implantation in both TRAMP-C1
prostate (Chen et al., 2011) and ALTS1C1 astrocytoma models
(Figure 6).
To further address the vascular issue, we used the anti-
angiogenic agent, sunitinib, to treat TRAMP-C1 tumor grown in
C57BL/6J mice. Anti-angiogenic agents, such as sunitinib, have
been proposed as potential candidates for clinical use in recurrent
tumors expressing high levels of angiogenic factors (Rauh-Hain
and Penson, 2008). Our previous study in TRAMP-C1 tumors
has shown that the administration of sunitinib could generate
a 3-day tumor growth delay, which is less than the effect of
25 Gy of IR. Although the effects of sunitinib on growth delay
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FIGURE 4 | Irradiation induces CD68+TAMs aggregation in hypoxic
regions in both ALTS1C1 and GL261 i.c. tumor models. The distribution of
CD68+TAMs and PIMO+ hypoxia in 8 Gy-irradiated ALTS1C1 astrocytoma
(A) and GL261 glioma (B) grown in the brain. Green: anti-PIMO stain for
hypoxic region; red: anti-CD68 antibody for TAMs. Merged images: the
colocalization of hypoxia and TAMs. Scale bar=100µm.
FIGURE 5 | Pre-irradiation induces CD68+TAMs aggregation in hypoxic
regions in ALTS1C1 tumors grown in both the brain (i.c.) and thigh (i.m.).
The correlation of CD68+TAMs with PIMO+ hypoxia in pre-irradiated
ALTS1C1 astrocytoma grown in the brain (i.c.) (A) or in the thigh (i.m.) (B).
Green: anti-PIMO stain for hypoxic region; red: anti-CD68 antibody for TAMs.
Merged images: the colocalization of hypoxia and TAMs. Bar: 100µm.
were modest, dramatic changes in tumor hypoxia and MVD were
found following sunitinib administration (Chen et al., 2011).
Many hypoxic regions in sunitinib-treated tumors did not have
vessels and were chronically hypoxic due to vascular insufficiency
(Figure 7), as seen in IR tumors. The center of the avascular
chronic hypoxic areas contained CD11b+ Gr-1+ cells, as was
seen in IR or pre-IR tumors. However, the aggregation of CD68+
TAMs into avascular hypoxic areas that was seen in IR or pre-IR
tumors did not exist in sunitinib-treated tumors (Figure 7). In fact,
most CD68+ TAMs accumulated in PIMO negative regions. This
demonstrates that the accumulation of CD68+TAMs in avascular
chronic hypoxia is a specific effect of RT and has less to do with
the decrease in MVD or the development of avascular chronic
hypoxia.
HYPOXIA-ASSOCIATED TAMs EXPRESS HIGHER LEVEL OF ARG I
Our early study using whole tumors has shown that CD11b+
TAMs isolated from irradiated tumors express higher level of Arg
I and had tumor-promoting activity (Tsai et al., 2007). However,
that approach cannot identify local environmental effects. In this
study, the expression of Arg-1 by randomly distributed-CD68+
TAMs (i.e., at PIMO− non-hypoxic regions) versus aggregated
CD68+TAMs (i.e., at avascular PIMO+ hypoxic regions) was fur-
ther verified in the ALTS1C1 intracranial model by IHC. Figure 8
shows CD68 and Arg-1 double staining in fluorescent imaging
taken from control, IR, or pre-IR tumor samples with the same
exposure time. It shows a higher percentage and intensity of Arg-1
staining in hypoxia-aggregated CD68+ TAMs than CD68+ TAMs
that are not aggregated in hypoxic area (Figure 8B). This indicates
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FIGURE 6 |The nature of PIMO+ hypoxic region in control and irradiated
tissues is different. The IHC staining for the distribution of hypoxia and
vascular in control (A,C), irradiated (B), or pre-irradiated (D) ALTS1C1 tumors.
The hypoxic regions in control tumors were vascularized. There was almost no
vasculature in the hypoxic regions of irradiated (B) or pre-irradiated tumors
(D). Green: anti-PIMO stain for hypoxic region; red: anti-CD31 antibody for
vessels. Merged images: the colocalization of hypoxia and vessels. Scale
bar=100µm.
FIGURE 7 | IHC staining for CD31,Gr-1, and CD68 in series sutent-treated
tumor sections. Administration of sutent decreased vascular density and
accumulated Gr-1+ cells at central necrosis in chronic hypoxia. However,
CD68+TAM does not aggregate at chronic hypoxia. Scale bar= 100µm.
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FIGURE 8 | AggregatedTAMs express higher level of Arg-1 than random
TAMs. (A) The IHC staining for the expression of Arg-1 by random or
aggregated CD68+TAMs in control, irradiated (IR) or pre-irradiated (pre-IR)
ALTS1C1 tumor Green: anti-Arg-1 antibody; red: anti-CD68 antibody. Merged
images: the colocalization of Arg-1 and TAMs. Scale bar=100µm. (B) The
percentage of Arg-1+TAMs (left graph) and the mean intensity of Arg-1
staining (right graph) by random or aggregated CD68+TAMs in control
(rectangular dot region), irradiated (IR) (white bar) or pre-irradiated (pre-IR)
(dark dot bar) ALTS1C1 tumors. The rectangular dot region represents the
average value±SD in control ALTS1C1 tumor for the purpose of clarity.
that hypoxia-aggregated TAMs could be more polarized toward an
M2 phenotype.
SDF-1α PLAYS A CRITICAL ROLE IN TAM AGGREGATION AND TUMOR
RE-GROWTH AFTER RT
SDF-1α production by ALTS1C1 is a critical factor for the accu-
mulation of TAMs in hypoxia (Wang et al., 2012). Knock down of
SDF-1(SDFkd) in ALTS1C1 tumors growing in a pre-irradiated
tissue also inhibited CD68+ TAM aggregation whether they
were grown i.c. (Figure 9A) or i.m. (Figure 9B). Tumor growth
delay was also further enhanced in both i.c. (Figure 9C) and
i.m. (Figure 9D) models when the expression of SDF-1α by
ALTS1C1 was suppressed by siRNA. This is further indirect evi-
dence to support the view that radiation-induced TAM aggrega-
tion in hypoxic areas stimulates tumor growth through SDF-1
production.
DISCUSSION
The interplay between TAMs and hypoxia is thought to be bi-
directional. Hypoxia-induced HIF-1α stabilization leads to the
expression of various angiogenic factors, such as VEGF, and
chemotactic factors, such as SDF-1α and CSF-1, by hypoxic tumor
cells. These factors further recruit peripheral macrophages to the
hypoxic regions to restore blood delivery and nourish the hypoxic
cells. The association of TAMs with hypoxia was originally thought
to be a natural link as is indicated by several renowned publica-
tions (Leek et al., 1999; Lewis et al., 1999, 2000; Crowther et al.,
2001; Burke et al., 2002; Murdoch and Lewis, 2005; Murdoch et al.,
2005; Degrossoli and Giorgio, 2007; Corzo et al., 2010). However,
our previous study in murine TRAMP-C1 prostate adenocarci-
noma demonstrated that the CD68+TAMs have no preference for
PIMO+ hypoxia region in the control, untreated tumors (Chen
et al., 2009). On the other hand, CD68+, but not F4/80+, TAMs
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FIGURE 9 | Suppression of SDF-1 expression by ALTS1C1 tumor disrupts
pre-IR-inducedTAM association with hypoxia in both i.c. (A) and i.m. (B)
models and prolong pre-IR-induced growth delay in both i.c. (C) and i.m.
(D) models. Green: anti-PIMO stain for hypoxic region; red: anti-CD68
antibody for TAMs. Merged images: the colocalization of hypoxia and TAMs.
Scale bar=100µm.
prefer to accumulate in PIMO+ hypoxia in intracranial ALTS1C1
astrocytoma. It appears that the association of CD68+ TAMs with
hypoxia is tumor dependent. This concept is further supported
here by another murine brain glioma, GL261, in which CD68+
TAMs do not have a preference for PIMO+ hypoxic regions.
It becomes more interesting when ALTS1C1 astrocytomas were
inoculated in the muscle, where the association of TAMs with
hypoxia seen in intracranial model disappeared. This indicates
that the association of TAMs with hypoxia is not only tumor
type dependent, but also stroma dependent. In other words, both
tumor-released factors and environmental cues determine TAM
function.
In this study, we used ALTS1C1 and GL262 tumors models
to demonstrate that the hypoxic regions in irradiated tumors or
tumors growing in pre-irradiated tissues had more CD68+ TAM
accumulation than control tumors. These results are in agree-
ment with our previous studies in TRAMP-C1 tumor model and
demonstrate their reproducibility in several tumors. Most PIMO+
hypoxic regions in control tumors contain CD31+ vessels, sug-
gesting that hypoxia resulted from abnormal vessel perfusion
and these may be transiently hypoxic. On the other hand, most
radiation-induced hypoxic regions did not contain CD31+ vessels,
indicating that the hypoxia is caused by insufficient blood vessels
and may be avascular chronic hypoxia. These radiation-induced
hypoxic regions frequently develop central necrosis and are filled
by Gr-1+ neutrophils. In fact, avascular chronic hypoxia could be
occasionally found in larger control tumors, but no CD68+ TAM
aggregation were found (Fu, S. Y. manuscript in preparation). This
indicates that radiation-induced hypoxic environments have spe-
cific factors that cause CD68+ TAM aggregation. This was further
supported by the use of the anti-angiogenic agent sunitinib, a
tyrosine kinase inhibitor that interrupts the signaling pathways
of endothelial growth factor receptor 1-3 and PDGF receptors α
and β. The sunitinib-treated tumors display the decrease of MVD
and the increase of avascular chronic hypoxia filled with Gr-1+
neutrophia as was seen in irradiated tumors. However, CD68+
TAMs do not accumulate in the avascular chronic hypoxic region
of sunitinib-treated tumors. Instead, even more CD68+ TAMs
were found in PIMO negative regions. This supports the notion
that irradiated hypoxic regions have factors to cause CD68+
TAM aggregation. Since the ALTS1C1 and GL261 tumors have
different CD68+ TAMs-hypoxia association patterns, microarray
and RT-PCR techniques were used to isolate the genes responsi-
ble. At least three monocytes-associated factors, SDF-1α, VEGF,
and MMP-2, were candidates. These factors have been separately
reported to be chemoattractant for macrophages (Lewis et al.,
2000; Gazitt and Akay, 2004; Kang et al., 2010) and induced by
hypoxia (Burke et al., 2003; Ide et al., 2006; Williams et al., 2006;
Zagzag et al., 2006; Chen et al., 2009; Wang et al., 2012). Previ-
ous studies have shown that RT can induce SDF-1α production
to promote the homing of hematopoietic progenitor cells toward
gliomas and enhance vessel formation (Tabatabai et al., 2006; Kioi
et al., 2010). We have also found that SDF-1α in the conditioned
medium produced by ALTS1C1 astrocytoma not only enhance
macrophage migration toward hypoxia, but also prolong their
survival in hypoxic condition (Wang et al., 2012). The current
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study further demonstrates that SDF-1α production by tumor
cells is one of factors that are responsible for the accumulation
of TAMs in radiation-induced hypoxic regions as its knock down
in ALTS1C1 tumor growing in intramuscular or intracranial pre-
irradiated sites prevented TAM accumulation in hypoxia. What
was more interesting was that the tumor growth delay was further
enhanced in SDF-1α-suppressed tumors. This implies: (1) that
SDF-1α promotes tumor growth in an irradiated microenviron-
ment or (2) that the association of TAMs with hypoxia enhances
tumor growth rate. If the latter is the case, it also indicates that
hypoxia-aggregated TAMs have an M2 phenotype, which is sup-
ported by Arg I staining being greater (both number and intensity)
in TAMs aggregated in hypoxic than non-hypoxic regions. This
further enhances the general view that TAMs in radiation-induced
hypoxia are of the M2 type and have better tumor-promoting
function.
In addition, this study also demonstrates that RT, no matter
given before or after tumor implantation, alters tumor microenvi-
ronments so that not TAM aggregate in hypoxic regions, and Gr-1
positive neutrophils, CD68+ TAMs, and F4/80+ TAMs reseg-
regate into different microenvironments. We believe that this is
the first report to show that three subtypes of monocytic cells
have their own niches in the irradiated tumor microenviron-
ment; these cells probably play different roles based on their
different locations, although we do not clearly know these roles
at the present. It is reasonable to speculate that the role of
Gr-1 positive neutrophils in the central necrotic regions is to
clean the debris in this area. The CD68+ TAMs within avas-
cular chronic hypoxia are likely associated with their M2 func-
tions. The roles or functions of F4/80+ TAMs at the junction
of avascular hypoxia and central necrosis need better under-
standing. However, it needs to caution that these changes fol-
lowing RT are stage dependent because the vascular damage and
chronic hypoxia following RT are dynamic, which depends on
radiation dose, tissues, and factors released by the tumors. For
example, the maximum hypoxia-induced TAM re-segregation for
TRAMP-C1 prostate tumor or ALTS1C1 astrocytoma grown in
the thigh following 25 Gy of radiation was at 3 week after RT.
The maximum effect for ALTS1C1 astrocytoma grown intracra-
nially following 8 or 15 Gy of radiations was at 3 or 2 week,
respectively, after RT (Wang, S. C. manuscript in prepara-
tion).
At the end, we have sorted out the relationship among tumor
cells, tumor microenvironments, and tumor response to RT. We
conclude that factors released from tumor cells are prime fac-
tors for the formation of specific type of tumor microenviron-
ments such as the association of TAMs with hypoxia. Among the
tumor microenvironments, MVD is the prime factor determining
the nature of hypoxia and the distribution of TAMs. Following
irradiation, radiation-induced tissue damage may release factors,
such as SDF-1α, that dominate the effects of original tumor-
or stroma-released factors. More importantly, this study shows
that the aggregation of CD68+ TAMs into hypoxic regions is
associated with the re-growth rate. This is further evidence to
support the view that CD68+ TAMs associated with chronic
hypoxia are likely M2 TAMs and a target for enhancing the effi-
cacy of RT. Tumor-secreted SDF-1α may not be the only factor
responsible for the TAM accumulation in hypoxic regions. Several
studies have also shown that hypoxia-induced iNOS expression
can also promote TAM migration (Weigert and Brune, 2008;
Zhou et al., 2009). However, the story for iNOS may be more
complex than SDF-1α because the hypoxic regions have lim-
ited supply for oxygen, the iNOS substrate (Robinson et al.,
2011).
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